Large deletions of chromosome 9p in cutaneous malignant melanoma identify patients with a high risk of developing metastases

S. Puig, J. Castro, P. J. Ventura, A. Ruiz, C. Ascaso, J. Malvehy, Xavier P. Estivill, J. M. Mascaro, M. Lecha, T. Castel

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Cutaneous malignant melanoma (CMM) is an aggressive tumour with a high metastatic potential. Deletions of chromosome 9p have been detected in CMM, some of which involve the CDKN2A/p14(ARF) genes. Loss of heterozygosity (LOH) of 16 microsatellite markers on 9p and mutations in the CDKN2A/p14(ARF) genes had been previously studied in 32 melanoma patients by our group. 9p deletions were detected in 15 primary tumours (45.5%) and are here correlated with the clinical outcome over 5 years and compared with classical prognostic factors. Eight of the 32 patients developed metastases (25%). The metastases were all detected within 768 days of the initial diagnosis. The patients without metastases were last monitored at least 1621 days after diagnosis. None of the 21 patients with more than eight microsatellites conserved developed metastases, whereas all of the eight patients who developed metastases had eight or more markers deleted. The sensitivity of this analysis to predict metastases was 100% (specificity 84%), whereas the sensitivity for the same sample using a Breslow thickness > 3 mm was 62.5% (specificity 68%). LOH of eight or more of the 9p microsatellite markers is therefore a useful prognostic factor to predict the development of metastases in the first 4.4-6.3 years (1621-2294 days). (C) 2000 Lippincott Williams and Wilkins.

Original languageEnglish
Pages (from-to)231-236
Number of pages6
JournalMelanoma Research
Volume10
Issue number3
Publication statusPublished - 2000
Externally publishedYes

Fingerprint

Chromosome Deletion
Neoplasm Metastasis
Tumor Suppressor Protein p14ARF
Microsatellite Repeats
Loss of Heterozygosity
Cutaneous Malignant Melanoma
Genes
Melanoma
Neoplasms
Mutation

Keywords

  • Chromosome 9p
  • Cutaneous melanoma
  • LOH
  • Melanoma
  • Microsatellites
  • Prognosis

ASJC Scopus subject areas

  • Oncology
  • Dermatology
  • Cancer Research

Cite this

Puig, S., Castro, J., Ventura, P. J., Ruiz, A., Ascaso, C., Malvehy, J., ... Castel, T. (2000). Large deletions of chromosome 9p in cutaneous malignant melanoma identify patients with a high risk of developing metastases. Melanoma Research, 10(3), 231-236.

Large deletions of chromosome 9p in cutaneous malignant melanoma identify patients with a high risk of developing metastases. / Puig, S.; Castro, J.; Ventura, P. J.; Ruiz, A.; Ascaso, C.; Malvehy, J.; Estivill, Xavier P.; Mascaro, J. M.; Lecha, M.; Castel, T.

In: Melanoma Research, Vol. 10, No. 3, 2000, p. 231-236.

Research output: Contribution to journalArticle

Puig, S, Castro, J, Ventura, PJ, Ruiz, A, Ascaso, C, Malvehy, J, Estivill, XP, Mascaro, JM, Lecha, M & Castel, T 2000, 'Large deletions of chromosome 9p in cutaneous malignant melanoma identify patients with a high risk of developing metastases', Melanoma Research, vol. 10, no. 3, pp. 231-236.
Puig, S. ; Castro, J. ; Ventura, P. J. ; Ruiz, A. ; Ascaso, C. ; Malvehy, J. ; Estivill, Xavier P. ; Mascaro, J. M. ; Lecha, M. ; Castel, T. / Large deletions of chromosome 9p in cutaneous malignant melanoma identify patients with a high risk of developing metastases. In: Melanoma Research. 2000 ; Vol. 10, No. 3. pp. 231-236.
@article{35db075f243e4f138f6bd0e3cfd1267f,
title = "Large deletions of chromosome 9p in cutaneous malignant melanoma identify patients with a high risk of developing metastases",
abstract = "Cutaneous malignant melanoma (CMM) is an aggressive tumour with a high metastatic potential. Deletions of chromosome 9p have been detected in CMM, some of which involve the CDKN2A/p14(ARF) genes. Loss of heterozygosity (LOH) of 16 microsatellite markers on 9p and mutations in the CDKN2A/p14(ARF) genes had been previously studied in 32 melanoma patients by our group. 9p deletions were detected in 15 primary tumours (45.5{\%}) and are here correlated with the clinical outcome over 5 years and compared with classical prognostic factors. Eight of the 32 patients developed metastases (25{\%}). The metastases were all detected within 768 days of the initial diagnosis. The patients without metastases were last monitored at least 1621 days after diagnosis. None of the 21 patients with more than eight microsatellites conserved developed metastases, whereas all of the eight patients who developed metastases had eight or more markers deleted. The sensitivity of this analysis to predict metastases was 100{\%} (specificity 84{\%}), whereas the sensitivity for the same sample using a Breslow thickness > 3 mm was 62.5{\%} (specificity 68{\%}). LOH of eight or more of the 9p microsatellite markers is therefore a useful prognostic factor to predict the development of metastases in the first 4.4-6.3 years (1621-2294 days). (C) 2000 Lippincott Williams and Wilkins.",
keywords = "Chromosome 9p, Cutaneous melanoma, LOH, Melanoma, Microsatellites, Prognosis",
author = "S. Puig and J. Castro and Ventura, {P. J.} and A. Ruiz and C. Ascaso and J. Malvehy and Estivill, {Xavier P.} and Mascaro, {J. M.} and M. Lecha and T. Castel",
year = "2000",
language = "English",
volume = "10",
pages = "231--236",
journal = "Melanoma Research",
issn = "0960-8931",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Large deletions of chromosome 9p in cutaneous malignant melanoma identify patients with a high risk of developing metastases

AU - Puig, S.

AU - Castro, J.

AU - Ventura, P. J.

AU - Ruiz, A.

AU - Ascaso, C.

AU - Malvehy, J.

AU - Estivill, Xavier P.

AU - Mascaro, J. M.

AU - Lecha, M.

AU - Castel, T.

PY - 2000

Y1 - 2000

N2 - Cutaneous malignant melanoma (CMM) is an aggressive tumour with a high metastatic potential. Deletions of chromosome 9p have been detected in CMM, some of which involve the CDKN2A/p14(ARF) genes. Loss of heterozygosity (LOH) of 16 microsatellite markers on 9p and mutations in the CDKN2A/p14(ARF) genes had been previously studied in 32 melanoma patients by our group. 9p deletions were detected in 15 primary tumours (45.5%) and are here correlated with the clinical outcome over 5 years and compared with classical prognostic factors. Eight of the 32 patients developed metastases (25%). The metastases were all detected within 768 days of the initial diagnosis. The patients without metastases were last monitored at least 1621 days after diagnosis. None of the 21 patients with more than eight microsatellites conserved developed metastases, whereas all of the eight patients who developed metastases had eight or more markers deleted. The sensitivity of this analysis to predict metastases was 100% (specificity 84%), whereas the sensitivity for the same sample using a Breslow thickness > 3 mm was 62.5% (specificity 68%). LOH of eight or more of the 9p microsatellite markers is therefore a useful prognostic factor to predict the development of metastases in the first 4.4-6.3 years (1621-2294 days). (C) 2000 Lippincott Williams and Wilkins.

AB - Cutaneous malignant melanoma (CMM) is an aggressive tumour with a high metastatic potential. Deletions of chromosome 9p have been detected in CMM, some of which involve the CDKN2A/p14(ARF) genes. Loss of heterozygosity (LOH) of 16 microsatellite markers on 9p and mutations in the CDKN2A/p14(ARF) genes had been previously studied in 32 melanoma patients by our group. 9p deletions were detected in 15 primary tumours (45.5%) and are here correlated with the clinical outcome over 5 years and compared with classical prognostic factors. Eight of the 32 patients developed metastases (25%). The metastases were all detected within 768 days of the initial diagnosis. The patients without metastases were last monitored at least 1621 days after diagnosis. None of the 21 patients with more than eight microsatellites conserved developed metastases, whereas all of the eight patients who developed metastases had eight or more markers deleted. The sensitivity of this analysis to predict metastases was 100% (specificity 84%), whereas the sensitivity for the same sample using a Breslow thickness > 3 mm was 62.5% (specificity 68%). LOH of eight or more of the 9p microsatellite markers is therefore a useful prognostic factor to predict the development of metastases in the first 4.4-6.3 years (1621-2294 days). (C) 2000 Lippincott Williams and Wilkins.

KW - Chromosome 9p

KW - Cutaneous melanoma

KW - LOH

KW - Melanoma

KW - Microsatellites

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=0033778508&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033778508&partnerID=8YFLogxK

M3 - Article

VL - 10

SP - 231

EP - 236

JO - Melanoma Research

JF - Melanoma Research

SN - 0960-8931

IS - 3

ER -